James Rodberg Sells 4,405 Shares of Sight Sciences (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CFO James Rodberg sold 4,405 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $7.82, for a total transaction of $34,447.10. Following the sale, the chief financial officer owned 154,440 shares in the company, valued at $1,207,720.80. This trade represents a 2.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

James Rodberg also recently made the following trade(s):

• On Tuesday, January 6th, James Rodberg sold 594 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total transaction of $4,443.12.

Sight Sciences Stock Down 0.4%

Shares of SGHT stock opened at $7.44 on Thursday. Sight Sciences, Inc. has a 12-month low of $2.03 and a 12-month high of $9.24. The company has a quick ratio of 8.93, a current ratio of 9.60 and a debt-to-equity ratio of 0.62. The firm has a fifty day moving average of $7.57 and a 200-day moving average of $5.15. The company has a market capitalization of $393.35 million, a price-to-earnings ratio of -8.27 and a beta of 2.42.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Wednesday, September 8th. The company reported ($0.81) earnings per share for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The company had revenue of $12.54 million during the quarter. As a group, equities research analysts predict that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Sight Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its position in Sight Sciences by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after buying an additional 3,785 shares during the last quarter. CWM LLC boosted its stake in shares of Sight Sciences by 70.2% during the 2nd quarter. CWM LLC now owns 7,607 shares of the company’s stock worth $31,000 after acquiring an additional 3,137 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Sight Sciences by 32.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock worth $48,000 after acquiring an additional 2,875 shares during the last quarter. Bank of Montreal Can bought a new stake in Sight Sciences in the 2nd quarter valued at $49,000. Finally, R Squared Ltd bought a new stake in Sight Sciences in the 3rd quarter valued at $64,000. Institutional investors own 55.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on SGHT. Piper Sandler set a $9.00 target price on Sight Sciences in a research note on Monday. Lake Street Capital lifted their target price on Sight Sciences from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, October 21st. Morgan Stanley upped their target price on Sight Sciences from $6.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Wall Street Zen upgraded Sight Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, September 13th. Finally, Raymond James Financial set a $9.00 price objective on Sight Sciences in a research note on Monday. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.30.

Trending Headlines about Sight Sciences

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight, which can attract buying from institutions and retail investors and support near-term positive sentiment. Read More.
• Neutral Sentiment: Key insiders still hold large stakes (CEO Paul Badawi ~5.9M shares; CTO David Badawi ~1.9M shares), which suggests ongoing long-term alignment despite recent sales and may limit fears of full insider exit. Read More.
• Negative Sentiment: Multiple executives (CEO, CTO, CFO, EVP and other insiders) disclosed sales between Jan. 2–6 totaling roughly $0.48M in proceeds. The clustered timing and size of the trades — even though each is a small percentage of holdings — can create short-term downward pressure or signal near‑term liquidity needs. Read More.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.